Depatuxizumab Mafodotin

Depatuxizumab Mafodotin (ABT-414) is an antibody drug conjugate (ADC) targeting EGFR-amplification that is being investigated to treat glioblastoma (GBM).

Type of Molecule

Biologic

Target

EGFR-amplification

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Glioblastoma (GBM) n/a
Phase 3
Pediatric Brain Tumors n/a
Phase 1